Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779298 | 1.00 | GPR119 (0.38) | GPR119JAK3PIKFYVEKDM4EALDH1A1 | |
| SCHEMBL5778002 | 0.85 | JAK3 (0.35) | JAK3PIKFYVEKDM4EALDH1A1GAA | |
| SCHEMBL5778000 | 0.85 | JAK3 (0.35) | JAK3PIKFYVEKDM4EALDH1A1GAA | |
| SCHEMBL5779193 | 0.82 | JAK3 (0.41) | GPR119JAK3KDM4EALDH1A1GAA | |
| SCHEMBL5779195 | 0.82 | JAK3 (0.41) | GPR119JAK3KDM4EALDH1A1GAA | |
| SCHEMBL5780415 | 0.78 | PKM (0.35) | GPR119KDM4EALDH1A1GAAMAPT | |
| SCHEMBL5775283 | 0.73 | LMNA (0.36) | PIKFYVEKDM4EALDH1A1GAAMAPT | |
| SCHEMBL5775279 | 0.73 | LMNA (0.36) | PIKFYVEKDM4EALDH1A1GAAMAPT | |
| SCHEMBL5780414 | 0.73 | IMPDH2 (0.39) | PIKFYVEKDM4EALDH1A1GAAMAPT | |
| SCHEMBL5778833 | 0.72 | MPO (0.56) | KDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | GPR119 2675/4885JAK3 4560/4885PIKFYVE 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.